Key result
Higher levels of interleukin-6 (quartile 4 vs 1) were independently associated with an increased risk of major adverse cardiovascular events (HR 1.60) in patients with stable coronary heart disease.
Why the study?
To review recent advances in pericoronary adipose tissue research and provide imaging-based insights supporting its clinical use in cardiovascular disease management.
Do elevated levels of inflammatory biomarkers IL-6 and hs-CRP independently predict cardiovascular events in patients with stable coronary heart disease?
Cohort (n=14,611)
Double-blind
Yes
Do elevated levels of inflammatory biomarkers IL-6 and hs-CRP independently predict cardiovascular events in patients with stable coronary heart disease?
In patients with stable coronary heart disease, IL-6 is an independent predictor of major adverse cardiovascular events and mortality, whereas hs-CRP loses its predictive value after multivariable adjustment.
Answers are grounded in this paper and cite their sources.
PCAT parameters may aid noninvasive coronary inflammation assessment; leaves open need for prospective outcome validation before clinical use.
Pericoronary adipose tissue (PCAT) plays an important role in the pathogenesis and progression of cardiovascular diseases due to its bidirectional communication with the coronary artery wall. In recent years, PCAT parameters measured using coronary computed tomography have emerged as potential noninvasive imaging biomarkers for quantifying coronary artery inflammation, with significant clinical value in the early detection, disease progression assessment, treatment efficacy evaluation, and prognosis prediction of cardiovascular diseases. Furthermore, new technologies such as PCAT radiomics analysis have broadened its potential applications in evaluating coronary plaque vulnerability, predicting cardiovascular events, and improving risk stratification. This review discusses recent advances in PCAT research, focusing on its role in coronary artery disease risk identification and inflammation monitoring, and aims to offer imaging-based insights to support its future clinical use in cardiovascular disease management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a cohort in Stable coronary heart disease (n=14,611). Interleukin-6 (IL-6) vs. Lowest quartile of IL-6 was evaluated on Major adverse cardiovascular events (MACE) (HR 1.60, 95% CI 1.30-1.97, p=<0.0001). Higher levels of interleukin-6 (quartile 4 vs 1) were independently associated with an increased risk of major adverse cardiovascular events (HR 1.60) in patients with stable coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: